Björn Cochlovius
Präsident bei BIOCURE TECHNOLOGY INC.
Profil
Björn Cochlovius is currently the Chief Executive Officer at Eleva GmbH and the Chief Executive Officer at Medraxa Therapeutics GmbH.
He is also the President at Biocure Technology, Inc. and the General Manager at BC Biomed Consulting GmbH.
In addition, Dr. Cochlovius is an Associate Professor at Ruprecht-Karls-Universität Heidelberg.
Previously, he served as the Chairman & Chief Executive Officer at Ciliatech Therapeutics AG and the Executive Chairman at Isogenica Ltd.
He was also the Chairman at Karolinska Development AB and Sapreme Technologies BV from 2020 to 2024.
Dr. Cochlovius held positions at Roche Holding AG, AbbVie, Inc., Affitech AS, and Affitech A.
He started his career as a Senior Vice President-Business Development at Atriva Therapeutics GmbH.
Dr. Cochlovius obtained his doctorate degree from Universität des Saarlandes.
Aktive Positionen von Björn Cochlovius
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOCURE TECHNOLOGY INC. | Präsident | 22.07.2021 |
| Medraxa Therapeutics GmbH | Vorstandsvorsitzender | - |
| BC Biomed Consulting GmbH | Vorstandsvorsitzender | - |
Eleva GmbH
 Eleva GmbH BiotechnologyHealth Technology Eleva GmbH develops biotechnology products and services. It offers Moss-aGal, Moss-GBA, Moss-FH, contract development and production, developmental pipeline, and technology transfer. The company was founded by Ralf Reski and Gunther Neuhaus in 1999 and is headquartered in Heilbronn, Germany. | Vorstandsvorsitzender | 03.05.2023 |
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 01.05.2003 |
Ehemalige bekannte Positionen von Björn Cochlovius
| Unternehmen | Position | Ende |
|---|---|---|
| KAROLINSKA DEVELOPMENT AB | Vorsitzender | 01.05.2024 |
Sapreme Technologies BV
 Sapreme Technologies BV BiotechnologyHealth Technology Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands. | Vorsitzender | 01.02.2024 |
| ROCHE HOLDING AG | Corporate Officer/Principal | - |
Ciliatech Therapeutics AG
 Ciliatech Therapeutics AG Pharmaceuticals: MajorHealth Technology Ciliatech Therapeutics AG is a Swiss company that focuses on researching, developing, producing, and distributing pharmaceutical and diagnostic products. | Vorstandsvorsitzender | - |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Björn Cochlovius
| Universität des Saarlandes | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| ABBVIE INC. | Health Technology |
| KAROLINSKA DEVELOPMENT AB | Finance |
| BIOCURE TECHNOLOGY INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Affitech AS /Old/
 Affitech AS /Old/ Miscellaneous Commercial ServicesCommercial Services Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway. | Commercial Services |
Eleva GmbH
Eleva GmbH BiotechnologyHealth Technology Eleva GmbH develops biotechnology products and services. It offers Moss-aGal, Moss-GBA, Moss-FH, contract development and production, developmental pipeline, and technology transfer. The company was founded by Ralf Reski and Gunther Neuhaus in 1999 and is headquartered in Heilbronn, Germany. | Health Technology |
Affitech A/S
 Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Health Technology |
Isogenica Ltd.
 Isogenica Ltd. Miscellaneous Commercial ServicesCommercial Services Isogenica Ltd. provides research and development services in the fields of new peptide, antibody and other polypeptide drug candidates. It offers llamdA System, Xab System and 4D Fab System. The company was founded by Kevin Fitzgerald in 2000 and is headquartered in Little Chesterford, the United Kingdom. | Commercial Services |
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
Sapreme Technologies BV
Sapreme Technologies BV BiotechnologyHealth Technology Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands. | Health Technology |
Ciliatech Therapeutics AG
Ciliatech Therapeutics AG Pharmaceuticals: MajorHealth Technology Ciliatech Therapeutics AG is a Swiss company that focuses on researching, developing, producing, and distributing pharmaceutical and diagnostic products. | Health Technology |
| Medraxa Therapeutics GmbH | |
| BC Biomed Consulting GmbH |
